GlaxoSmithKline: Phase 3 Study of Zejula Met Trial Objectives
15 Julio 2019 - 1:43AM
Noticias Dow Jones
By Carlo Martuscelli
GlaxoSmithKline PLC (GSK.LN) said Monday that a phase 3 study of
its cancer drug niraparib, which is marketed under the name Zejula,
yielded positive results.
The drug demonstrated a statistically-meaningful improvement in
survival without disease progression in women with ovarian cancer,
regardless of their biomarker status, the British pharmaceutical
company said.
Safety results were consistent with previous clinical trials.
The medication was being administered as a first-line maintenance
treatment following platinum based chemotherapy.
GlaxoSmithKline said full results from the study, called Prima,
will be made public at an upcoming scientific meeting.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
July 15, 2019 02:28 ET (06:28 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024